Disease · HP_0000741
Apathy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Apathy. Diseases, record HP_0000741. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000741
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Apathy
- Open Targets ID
- HP_0000741
- Other names
- Lack of feeling, emotion, interest, Lack of feeling, emotion, interest, motivation, initiation, State of indifference
- Highest stage of its drugs
- Phase 3, for 7 of its 10 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE | CHEMBL796 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BUPROPION | CHEMBL894 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LUMATEPERONE | CHEMBL3306803 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MODAFINIL | CHEMBL1373 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVASTIGMINE | CHEMBL636 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROTIGOTINE | CHEMBL1303 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYTOCIN | CHEMBL395429 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RAZPIPADON | CHEMBL3697578 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISTRADEFYLLINE | CHEMBL431770 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 3 | D2-like dopamine receptor agonist; Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| SLC6A3 | Sodium-dependent dopamine transporter | 3 | Dopamine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 2 | Norepinephrine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| ACHE | Cholinesterases; ACHE & BCHE | 1 | Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADORA2A | Adenosine receptor A2a | 1 | Adenosine A2a receptor antagonist | Unknown | https://conductscience.org/library/genes/135 | Drugs and targets |
| BCHE | Cholinesterases; ACHE & BCHE | 1 | Cholinesterases; ACHE & BCHE inhibitor | Phase 3 | https://conductscience.org/library/genes/590 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor agonist | Phase 3 | https://conductscience.org/library/genes/1815 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 1 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02346201 | Apathy in Dementia Methylphenidate Trial 2 | Phase 3 | 200 | 2023-06-13 | Apathy, Alzheimer's Disease | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT00548652 | Role of Apathy in the Effectiveness of Weight Loss Interventions | Not applicable | 101 | 2019-10-04 | Obesity, Apathy | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT01117181 | Apathy in Dementia Methylphenidate Trial (ADMET) | Phase 2 | 60 | 2013-05-10 | Apathy, Alzheimer's Disease | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT04958031 | A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | Phase 2 | 41 | 2026-03-11 | Apathy in Dementia | RAZPIPADON | Its record names the disease | ClinicalTrials.gov |
| NCT01172145 | Treatment of Apathy in Alzheimer's Disease With Modafinil | Phase 3 | 22 | 2011-03-04 | Apathy, Alzheimer's Disease | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT02786667 | Non Motors Aspects in De Novo Parkinson's Disease | Phase 3 | 199 | Parkinson Disease, Apathy | ROTIGOTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03260920 | Intranasal Oxytocin for Frontotemporal Dementia | Phase 2 | 112 | Frontotemporal Dementia | OXYTOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01047254 | Bupropion for the Treatment of Apathy in Alzheimer's Dementia | Phase 3 | 110 | Apathy in Dementia | BUPROPION | Its record names the disease | ClinicalTrials.gov | |
| NCT06482554 | Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | Phase 3 | 80 | Apathy, Schizophrenia, Schizophrenia; Psychosis | LUMATEPERONE, RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00767091 | Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia | Phase 3 | 40 | Parkinson's Disease, Apathy, no Dementia | RIVASTIGMINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Methylphenidate vs Placebo: deaths from any cause | 0 of 99 | 0 of 101 | 200 | NCT02346201 | Trial comparisons |
| Methylphenidate vs Placebo: serious adverse events | 13 of 99 | 9 of 101 | 200 | NCT02346201 | Trial comparisons |
| Methylphenidate vs Placebo: serious adverse events | 1 of 29 | 1 of 31 | 60 | NCT01117181 | Trial comparisons |
| Cholinesterase Inhibitor Only vs Cholinesterase Plus Modafinil: serious adverse events | 0 of 11 | 0 of 11 | 22 | NCT01172145 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000741
GET https://conductscience.org/api/diseases/v1/HP_0000741/drugs